Bridget Nance, APRN
Acute Care · Salem, OHNPI 1184278863
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,757 of the $4,642 with a category attached, or 80.9%. 15 manufacturers reported payments, led by Pulmonx Corporation at 32.4% of the total. 2025 is the largest year on record at $2,578, more than ten times the $114 reported in 2022. Among acute care clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 84 payments — averaging $55.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pulmonx Corporation$2K
- AstraZeneca$1K
- United Therapeutics Corporation$705
- Regeneron Healthcare Solutions, Inc.$401
- Boehringer Ingelheim$322
- GSK$222
- plus $474 from 9 others
What the payments were for
- Travel & lodging$78217%
- Food & beverage$3,75781%
- Education$1042%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pulmonx Corporation | 11 | $1,504 |
| AstraZeneca | 17 | $1,014 |
| United Therapeutics Corporation | 15 | $705 |
| Regeneron Healthcare Solutions, Inc. | 10 | $401 |
| Boehringer Ingelheim | 4 | $322 |
| GSK | 8 | $222 |
| Insmed, Inc. | 11 | $213 |
| Actelion Pharmaceuticals US, Inc. | 1 | $107 |
| Biomerieux Inc | 1 | $27 |
| Verona Pharma, Inc. | 1 | $24 |
| Aurinia Pharma U.S., Inc. | 1 | $23 |
| Merck | 1 | $23 |
| Grifols USA, LLC | 1 | $21 |
| Baxter Healthcare | 1 | $18 |
| Sanofi | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ZEPHYR ENDOBRONCHIAL VALVE$1,361
- CHARTIS CATHETER$417
- ZEPHYR DELIVERY CATHETER$417
- PULMONX CHARTIS TABLET CONSOLE$417
- TEZSPIRE$125
- OFEV$123
- FASENRA$123
- DUPIXENT$121
- UPTRAVI$107
- OPSUMIT$107
How this compares
$4,642 in reported general payments places this provider in the 95th percentile of 1,101 acute care providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 285 | $264,726 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 120 | $80,677 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 39 | $28,415 |
| Breo ElliptaFluticasone/Vilanterol | 23 | $15,525 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 15 | $12,142 |
| Spiriva RespimatTiotropium Bromide | 17 | $9,819 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 297 | $8,928 |
| SymbicortBudesonide/Formoterol Fumarate | 25 | $8,165 |
| DuleraMometasone/Formoterol | 14 | $4,996 |
| Ventolin HfaAlbuterol Sulfate | 39 | $4,234 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 17 | $4,062 |
| Incruse ElliptaUmeclidinium Bromide | 13 | $3,760 |
| Levalbuterol Tartrate HfaLevalbuterol Tartrate | 25 | $1,355 |
| Roflumilast | 28 | $1,213 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 19 | $1,154 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta | $222 | $296,153336 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $1,014 | $88,842145 claims |
| Boehringer IngelheimStiolto Respimat, Spiriva Respimat | $322 | $38,23456 claims |
| MerckDulera | $23 | $4,99614 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,101 acute care providers in Ohio.
Other acute care in Salem
- Andrea RobinsonCleveland$149K
- Brittney BrowneMonroe$142K
- Jamie McGuireMiamisburg$86K
- Ileah ReichertColumbus$73K
- Davida PraterBeavercreek$46K
- Dawn FrenchAlliance$40K
- Holly McKibbenColumbus$23K
- Jody HussBlue Ash$13K
- Julie LurieCincinnati$13K
- Susan BrooksMount Vernon$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.